
Welcome to DiaGenic Capital Markets Day



The seminar will focus on the markets for DiaGenic's two business areas: Biomarkers and Molecular Diagnostics.

The speakers will address important topics regarding positioning of DiaGenic's first two diagnostic tests for Breast Cancer (BCtect®), and Alzheimer's Disease (ADtect®).

In these challenging financial markets, we would also like to share some evaluations from international investors.

The list of speakers includes:

"DiaGenic Report for 1st quarter 2009"

MD PhD Erik Christensen, Managing Director, DiaGenic

BCtect®

Derek Tobin, Ph.D., Senior Scientist & Project Manager Breast Cancer, DiaGenic

ADtect®

Birgitte Bonstra Booij, Ph. D., Senior Scientist & Project Manager Alzheimer's Disease, DiaGenic

"Sales and Distribution partners in Europe"

Morten Sten Johansen, International Business Director, DiaGenic

"From research into clinical practice with BCtect®"

Dr James Mackay, Trinity Health Innovations Ltd, London
James Mackay is honorary senior lecturer in genetics at University College London

"Biomarkers in CNS drug development"

Sebastian Krempien, M.D. Ph.D., Senior Medical Expert
Merz Pharmaceuticals GmbH, Frankfurt / Main
Sebastian Krempien is heading the Merz CNS Biomarker Team

"Need for early detection of breast cancer worldwide"

Bjarte Reve, Managing Director, Oslo Cancer Cluster Bjarte Reve is recently appointed "Young Global Leader".

"Managing Life Science investments in turbulent times"

Ulrica Slåne, Portfolio manager AP3, Third Swedish National Pension Fund, Stockholm.

Ulrica Slåne is managing the Life Science Investment Fund of AP3

"DiaGenic: a UK-investor perspective"

Keith Redpath, Research Director, FinnCap, London.

Keith Redpath covers Life Science companies for JMFinn Capital Markets Limited.

Date: 11th of May

Time:

4 pm - 7 pm Tapas & Wine will be served.

Place:

DIAGENIC, Grenseveien 92, Oslo

Phone:

+47 23 24 78 52